{
    "Trade/Device Name(s)": [
        "NG-Test CARBA 5"
    ],
    "Submitter Information": "NG Biotech",
    "510(k) Number": "K191889",
    "Predicate Device Reference 510(k) Number(s)": [
        "K162385"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PTJ"
    ],
    "Summary Letter Date": "October 2, 2019",
    "Summary Letter Received Date": "July 15, 2019",
    "Submission Date": "July 11, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.1640"
    ],
    "Regulation Name(s)": [
        "Antimicrobial Susceptibility Test Powder"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "KPC carbapenemase",
        "OXA-48-like carbapenemase",
        "VIM carbapenemase",
        "IMP carbapenemase",
        "NDM carbapenemase"
    ],
    "Specimen Type(s)": [
        "Pure bacterial colonies",
        "Raw stool inoculated to HardyCHROM CRE agar",
        "C&S Cary Blair stool inoculated to HardyCHROM CRE agar"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "NG-Test CARBA 5 cassette"
    ],
    "Method(s)/Technology(ies)": [
        "Multiplex immunochromatographic assay",
        "Lateral flow assay"
    ],
    "Methodologies": [
        "Qualitative detection",
        "Immunochromatographic assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Cassette",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for NG-Test CARBA 5 rapid multiplex immunochromatographic assay to detect and differentiate five common carbapenemases in bacterial colonies",
    "Indications for Use Summary": "Qualitative detection and differentiation of KPC, OXA-48-like, VIM, IMP, and NDM carbapenemases in carbapenem non-susceptible pure bacterial colonies for infection control in healthcare settings; not intended to guide or monitor treatment.",
    "fda_folder": "Microbiology"
}